<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Guo X</submitter><funding>NIDDK NIH HHS</funding><funding>University of Pittsburgh</funding><funding>NIAID NIH HHS</funding><funding>RRD VA</funding><funding>National Institutes of Health</funding><funding>U.S. Department of Veterans Affairs</funding><funding>NIH HHS</funding><pagination>112733</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10691306</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>42(7)</volume><pubmed_abstract>Variants of the RNA-editing enzyme ADAR1 cause Aicardi-Goutières syndrome (AGS), in which severe inflammation occurs in the brain due to innate immune activation. Here, we analyze the RNA-editing status and innate immune activation in an AGS mouse model that carries the Adar P195A mutation in the N terminus of the ADAR1 p150 isoform, the equivalent of the P193A human Zα variant causal for disease. This mutation alone can cause interferon-stimulated gene (ISG) expression in the brain, especially in the periventricular areas, reflecting the pathologic feature of AGS. However, in these mice, ISG expression does not correlate with an overall decrease in RNA editing. Rather, the enhanced ISG expression in the brain due to the P195A mutant is dose dependent. Our findings indicate that ADAR1 can regulate innate immune responses through Z-RNA binding without changing overall RNA editing.</pubmed_abstract><journal>Cell reports</journal><pubmed_title>ADAR1 Zα domain P195A mutation activates the MDA5-dependent RNA-sensing signaling pathway in brain without decreasing overall RNA editing.</pubmed_title><pmcid>PMC10691306</pmcid><funding_grant_id>I01 RX001455</funding_grant_id><funding_grant_id>P30 DK120531</funding_grant_id><funding_grant_id>R01AI139544</funding_grant_id><funding_grant_id>S10OD028483</funding_grant_id><funding_grant_id>S10 OD028483</funding_grant_id><funding_grant_id>R01 AI139544</funding_grant_id><funding_grant_id>I01RX001455</funding_grant_id><pubmed_authors>Zenati M</pubmed_authors><pubmed_authors>Sheng Y</pubmed_authors><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>Guo X</pubmed_authors><pubmed_authors>Billiar T</pubmed_authors><pubmed_authors>Herbert A</pubmed_authors><pubmed_authors>Liu S</pubmed_authors></additional><is_claimable>false</is_claimable><name>ADAR1 Zα domain P195A mutation activates the MDA5-dependent RNA-sensing signaling pathway in brain without decreasing overall RNA editing.</name><description>Variants of the RNA-editing enzyme ADAR1 cause Aicardi-Goutières syndrome (AGS), in which severe inflammation occurs in the brain due to innate immune activation. Here, we analyze the RNA-editing status and innate immune activation in an AGS mouse model that carries the Adar P195A mutation in the N terminus of the ADAR1 p150 isoform, the equivalent of the P193A human Zα variant causal for disease. This mutation alone can cause interferon-stimulated gene (ISG) expression in the brain, especially in the periventricular areas, reflecting the pathologic feature of AGS. However, in these mice, ISG expression does not correlate with an overall decrease in RNA editing. Rather, the enhanced ISG expression in the brain due to the P195A mutant is dose dependent. Our findings indicate that ADAR1 can regulate innate immune responses through Z-RNA binding without changing overall RNA editing.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jul</publication><modification>2025-05-29T21:25:47.139Z</modification><creation>2025-02-19T01:18:29.255Z</creation></dates><accession>S-EPMC10691306</accession><cross_references><pubmed>37421629</pubmed><doi>10.1016/j.celrep.2023.112733</doi></cross_references></HashMap>